Apimeds Pharmaceuticals US Inc (APUS) is a digital asset technology company that provides institutional Bitcoin treasury and digital asset technology (DAT) solutions to corporate treasuries, institutions, and financial intermediaries. The company plans to generate revenue by delivering compliant, risk-managed infrastructure enabling enterprises to hold and manage Bitcoin as a treasury reserve asset. As of the 10-K filed May 4, 2026, the business had not yet generated material operating revenue and reported a net loss per share of $(0.55) for the year ended December 31, 2025, on weighted-average shares outstanding of 10,881,907. Cash and cash equivalents stood at $1.6 million, with restricted cash of $8.0 million and short-term investments of $2.0 million, for total liquidity of $11.6 million as of December 31, 2025. The company also retains legacy pharmaceutical regulatory assets, reflected in filings that reference FDA Biologics License Application processes, though no pharmaceutical revenue is disclosed in the excerpts.

Revenue model

No revenue has been disclosed in the filing excerpts for FY2025. The intended model is transactional and service-based fees from enterprise clients for institutional Bitcoin treasury management and DAT solutions, distributed directly through internal business development teams and via partnerships with custodians, wallet providers, and financial institutions.

Products and services

Institutional Bitcoin treasury solutions and digital asset technology (DAT) platforms targeting corporate treasury adoption of Bitcoin as a reserve asset. Supporting services include secure custody frameworks, segregation and control infrastructure, execution services for Bitcoin acquisitions and dispositions, validator operations, and programmatic risk management, delivered in partnership with regulated custodians and institutional-grade wallet providers.

Customers and end markets

Target customers are corporate treasuries, institutional investors, investment funds, and financial intermediaries evaluating or adopting Bitcoin reserve strategies. The filing also references placement agents and enterprise software integrators as distribution partners.

Value-chain role

Platform and enablement layer sitting between enterprise clients and regulated custody, execution, and intermediation infrastructure. The company does not hold direct custody, execution, or intermediation licenses; it relies on third-party partners to supply that regulatory infrastructure.

Geographic exposure

Not specified in the filing excerpts.

Source: SEC 10-K, filed 2026-05-04

Industry: Pharmaceutical Preparations